ES2871052T3 - Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa - Google Patents
Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa Download PDFInfo
- Publication number
- ES2871052T3 ES2871052T3 ES12792550T ES12792550T ES2871052T3 ES 2871052 T3 ES2871052 T3 ES 2871052T3 ES 12792550 T ES12792550 T ES 12792550T ES 12792550 T ES12792550 T ES 12792550T ES 2871052 T3 ES2871052 T3 ES 2871052T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- unsubstituted
- oxide
- azaphosphinan
- phthalazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C1)NCCP1(*)=* Chemical compound CC(C1)NCCP1(*)=* 0.000 description 7
- KNHJLNSESCKUKI-UHFFFAOYSA-N COC(c(cc(cc1)F)c1C#Cc(cc1Br)ccc1F)=O Chemical compound COC(c(cc(cc1)F)c1C#Cc(cc1Br)ccc1F)=O KNHJLNSESCKUKI-UHFFFAOYSA-N 0.000 description 1
- BRUNIDAHRLZQOH-UHFFFAOYSA-N COC(c(cc(cc1)F)c1I)=O Chemical compound COC(c(cc(cc1)F)c1I)=O BRUNIDAHRLZQOH-UHFFFAOYSA-N 0.000 description 1
- RDXMKIOPAQRRKQ-UHFFFAOYSA-N O=C(c1c2)NN=C(Cc(cc3P4(CCN(Cc5ccccc5)CC4)=O)ccc3F)c1ccc2F Chemical compound O=C(c1c2)NN=C(Cc(cc3P4(CCN(Cc5ccccc5)CC4)=O)ccc3F)c1ccc2F RDXMKIOPAQRRKQ-UHFFFAOYSA-N 0.000 description 1
- NYSJHCBHBQAYFX-UHFFFAOYSA-N O=C1NN=C(Cc(cc2)cc(P(CC3)(CCN3C3CC3)=O)c2F)c(cc2)c1cc2F Chemical compound O=C1NN=C(Cc(cc2)cc(P(CC3)(CCN3C3CC3)=O)c2F)c(cc2)c1cc2F NYSJHCBHBQAYFX-UHFFFAOYSA-N 0.000 description 1
- LXPAEQXCSCAYJX-UHFFFAOYSA-N O=C1NN=C(Cc(cc2)cc(P3(CCN(CC(F)(F)F)CC3)=O)c2F)c2ccccc12 Chemical compound O=C1NN=C(Cc(cc2)cc(P3(CCN(CC(F)(F)F)CC3)=O)c2F)c2ccccc12 LXPAEQXCSCAYJX-UHFFFAOYSA-N 0.000 description 1
- NKWRNNXACOVHNK-UHFFFAOYSA-N O=C1NN=C(Cc(cc2Br)ccc2F)c(cc2)c1cc2F Chemical compound O=C1NN=C(Cc(cc2Br)ccc2F)c(cc2)c1cc2F NKWRNNXACOVHNK-UHFFFAOYSA-N 0.000 description 1
- KUDVXLARCFBRBX-UHFFFAOYSA-N O=C1NN=C(Cc(cc2P3(CCNCC3)=O)ccc2F)c(cc2)c1cc2F Chemical compound O=C1NN=C(Cc(cc2P3(CCNCC3)=O)ccc2F)c(cc2)c1cc2F KUDVXLARCFBRBX-UHFFFAOYSA-N 0.000 description 1
- BRATYQVOINPFFS-UHFFFAOYSA-N O=C1NN=C(Cc(cc2P3(CCNCC3)=O)ccc2F)c2ccccc12 Chemical compound O=C1NN=C(Cc(cc2P3(CCNCC3)=O)ccc2F)c2ccccc12 BRATYQVOINPFFS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161491851P | 2011-05-31 | 2011-05-31 | |
| PCT/US2012/040304 WO2012166983A1 (en) | 2011-05-31 | 2012-05-31 | Tricyclic inhibitors of poly(adp-ribose)polymerase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2871052T3 true ES2871052T3 (es) | 2021-10-28 |
Family
ID=47259874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12792550T Active ES2871052T3 (es) | 2011-05-31 | 2012-05-31 | Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20140221314A1 (enExample) |
| EP (2) | EP3925962A1 (enExample) |
| JP (1) | JP5960253B2 (enExample) |
| CN (1) | CN103717609B (enExample) |
| CA (1) | CA2875025C (enExample) |
| ES (1) | ES2871052T3 (enExample) |
| TW (1) | TWI577693B (enExample) |
| WO (1) | WO2012166983A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3925962A1 (en) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
| DK2938598T3 (en) | 2012-12-31 | 2017-02-13 | Cadila Healthcare Ltd | Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| US10562886B2 (en) | 2015-05-21 | 2020-02-18 | The Regents Of The University Of California | Anti-cancer compounds |
| WO2017223516A1 (en) | 2016-06-24 | 2017-12-28 | The Regents Of The University Of California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
| CN111936143A (zh) * | 2018-04-05 | 2020-11-13 | 诺维嘉研究公司 | 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品 |
| CN119390683A (zh) | 2019-08-15 | 2025-02-07 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| CN112574122B (zh) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | 一种奥拉帕尼关键中间体的制备方法 |
| CN114276301B (zh) * | 2020-09-27 | 2025-04-01 | 江西科睿药业有限公司 | Parp抑制剂的中间体化合物及其制备方法和应用 |
| CN112624981B (zh) * | 2021-03-09 | 2021-05-25 | 南京桦冠生物技术有限公司 | 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE218556T1 (de) | 1995-11-17 | 2002-06-15 | Biotechnolog Forschung Gmbh | Epothilon-derivate und deren herstellung |
| US6242469B1 (en) | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Ｋｄｒに特異的な抗体およびその使用 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| AU4972900A (en) | 1999-04-08 | 2000-11-14 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
| AU9578901A (en) | 2000-10-30 | 2002-05-15 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7151102B2 (en) * | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7402580B2 (en) | 2002-02-19 | 2008-07-22 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| AU2004220321B2 (en) * | 2003-03-12 | 2010-02-25 | Kudos Pharmaceuticals Ltd | Phthalazinone derivatives |
| EP1791827A1 (en) | 2004-08-26 | 2007-06-06 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| JP2009544611A (ja) * | 2006-07-20 | 2009-12-17 | メルク エンド カムパニー インコーポレーテッド | ヒストン脱アセチル化酵素阻害剤としてのリン誘導体 |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| PT2698062E (pt) | 2006-12-28 | 2015-10-19 | Abbvie Inc | Inibidores da poli (adp-ribose) polimerase |
| US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| TW200900396A (en) | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
| AU2008313467B2 (en) * | 2007-10-17 | 2013-08-29 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one |
| WO2009063244A1 (en) | 2007-11-15 | 2009-05-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Pyridazinone derivatives as parp inhibitors |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| EP2300013B2 (en) * | 2008-05-21 | 2024-11-13 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| NZ597140A (en) * | 2009-06-05 | 2014-01-31 | Cephalon Inc | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| JP5721709B2 (ja) | 2009-07-02 | 2015-05-20 | ニューゲン セラピューティクス， インコーポレイテッド | リンを含むキナゾリン化合物および使用方法 |
| EP3925962A1 (en) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
-
2012
- 2012-05-31 EP EP21161257.7A patent/EP3925962A1/en not_active Withdrawn
- 2012-05-31 ES ES12792550T patent/ES2871052T3/es active Active
- 2012-05-31 WO PCT/US2012/040304 patent/WO2012166983A1/en not_active Ceased
- 2012-05-31 EP EP12792550.1A patent/EP2714703B1/en active Active
- 2012-05-31 US US14/122,983 patent/US20140221314A1/en not_active Abandoned
- 2012-05-31 JP JP2014513717A patent/JP5960253B2/ja active Active
- 2012-05-31 CA CA2875025A patent/CA2875025C/en active Active
- 2012-05-31 CN CN201280024255.0A patent/CN103717609B/zh active Active
- 2012-05-31 TW TW101119653A patent/TWI577693B/zh active
-
2016
- 2016-04-01 US US15/089,131 patent/US20170057984A1/en not_active Abandoned
-
2017
- 2017-06-15 US US15/624,201 patent/US20180094010A1/en not_active Abandoned
-
2019
- 2019-10-28 US US16/666,307 patent/US11248013B2/en active Active
-
2022
- 2022-02-14 US US17/671,436 patent/US12612425B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012166983A1 (en) | 2012-12-06 |
| US12612425B2 (en) | 2026-04-28 |
| EP3925962A1 (en) | 2021-12-22 |
| JP2014516989A (ja) | 2014-07-17 |
| EP2714703A1 (en) | 2014-04-09 |
| US20170057984A1 (en) | 2017-03-02 |
| US11248013B2 (en) | 2022-02-15 |
| TWI577693B (zh) | 2017-04-11 |
| JP5960253B2 (ja) | 2016-08-02 |
| US20180094010A1 (en) | 2018-04-05 |
| CA2875025A1 (en) | 2012-12-06 |
| CN103717609B (zh) | 2016-05-11 |
| US20200299315A1 (en) | 2020-09-24 |
| CA2875025C (en) | 2021-08-03 |
| EP2714703A4 (en) | 2014-12-31 |
| CN103717609A (zh) | 2014-04-09 |
| EP2714703B1 (en) | 2021-03-10 |
| US20230027257A1 (en) | 2023-01-26 |
| TW201311713A (zh) | 2013-03-16 |
| US20140221314A1 (en) | 2014-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12612425B2 (en) | Tricyclic inhibitors of poly(ADP-ribose)polymerase | |
| CA3011189C (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| ES2780928T3 (es) | Compuestos de espiroimidazol y su uso como inhibidores de bace | |
| WO2023062575A1 (en) | Cyclic vinyl sulfone compounds as wrn inhibitors | |
| ES2548131T3 (es) | Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida | |
| ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
| EP3016945B1 (en) | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors | |
| TW202106670A (zh) | 用於治療癌症之醯基磺醯胺 | |
| UA123785C2 (uk) | Сполуки піролотриазину як інгібітори tam | |
| UA121036C2 (uk) | 2-(морфолін-4-іл)-1,7-нафтиридини | |
| TWI528961B (zh) | 作為聚（ａｄｐ-核糖）聚合酶（ｐａｒｐ）抑制劑之經醯胺取代之吲唑 | |
| UA123813C2 (uk) | Заміщені індазоли, способи їх одержання, фармацевтичні препарати, які їх містять, та їх застосування для одержання лікарських засобів | |
| CA2732797A1 (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | |
| EP3019171B1 (en) | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) | |
| AU2017389818B2 (en) | Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof | |
| CN118055933A (zh) | 选择性parp1抑制剂及其应用 | |
| ES2773511T3 (es) | Derivados de 1,4-dicarbonil-piperidilo | |
| JP2025535496A (ja) | 化合物及びその使用 | |
| JP2020523361A (ja) | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤、調製方法および使用 | |
| KR20260019517A (ko) | 3,4-디히드로프탈라진-1(2h)-온 유도체, 및 이의 제조 방법 및 이의 용도 | |
| JP7763538B2 (ja) | Ｐａｒｐ７阻害剤及びその使用 | |
| ES2720525T3 (es) | Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfona | |
| EA051813B1 (ru) | Пиразолопиримидиновое соединение, его фармацевтическая композиция, способ лечения и применение | |
| HK1177462B (en) | Triazolopyridine derivatives |